Background: The aim was to elucidate clinical trial efficacy, safety, and dosing practices of abobotulinumtoxinA (ABO) treatment in adult patients with
Introduction
Blepharospasm and hemifacial spasm are disabling movement disorders involving the facial muscles that are routinely treated with botulinum neurotoxin type A (BoNT-A).
Blepharospasm is a focal dystonia characterized by excessive involuntary blinking or forceful closure of the eyelids. In the most common primary form (benign essential blepharospasm), symptoms are caused by spasm of the orbicularis oculi muscles. 1 Involuntary
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The Center for Digital Research and Scholarship Columbia University Libraries/Information Services closure of the eyelids can also be caused by failure of voluntary levator contraction, a condition known as "apraxia of lid opening"; the two conditions may co-exist. 2 Patients with mild blepharospasm can present with eyestrain and a sensation of dryness in the eyes that contributes to excessive blinking. These symptoms are sometimes difficult for physicians to distinguish from tic disorders, though tics involving the face are more likely to be suppressible for brief periods and generally do not improve with the use of a "sensory trick." With progression of the disorder some patients find it increasingly hard to keep their eyes open, leading to a functional blindness because of frequent and prolonged eyelid closure. In addition, the condition can be associated with depression, anxiety and social isolation. 3 Like other forms of dystonia, the pathophysiology of blepharospasm has not been clearly defined, but seems to be correlated with basal ganglia function and impaired neuroplasticity. 1 Hemifacial spasm (HFS) is characterized by unilateral intermittent clonic or tonic contraction of the muscles responsible for facial expression. These muscles are supplied by the facial nerve, and the most likely cause of HFS is a blood vessel compressing the root of this nerve. 4 Other etiologies of HFS are similarly related to injury of the facial nerve, and may develop after facial reconstruction surgeries or Bell's palsy. The disorder typically begins around the eye and this often is the most symptomatic aspect to the disorder. HFS can have a significant impact on a patient's quality of life. 5 The integral role of BoNT-A in the management of blepharospasm and HFS is recognized by guidelines from around the world. 6, 7 The American Academy of Neurology (AAN) evidence-based treatment guidelines for blepharospasm and HFS recommend that BoNT should be offered as a treatment option to patients with blepharospasm (Level B) and hemifacial spasm (Level C). 6 At present, none of the BoNT-A is approved for the treatment of HFS in the United States. To date, most literature reviews for blepharospasm and HFS have examined the effectiveness of all BoNT products as a class. 6, 8, 9 However, differences in dosing units and recommended schemes provide a clear rationale for reviewing each product separately. In the United States, this principle is emphasized by mandatory Food and Drug Administration (FDA) labeling stating that BoNT subtypes are not interchangeable and no standard dose adjustments should be used to substitute one subtype for another. Indeed, education on the specifics of each product is a key unmet need in the medical community, as the lack of direct product comparability leads to confusion and therefore potentially sub-optimal treatment. AbobotulinumtoxinA (ABO) has been used to treat blepharospasm and HFS in many countries outside the United States for many years. [10] [11] [12] We have previously reported on a systematic review evaluating the use of ABO in the management of adult upper limb spasticity. 13 Here we report the results of a parallel systematic review of clinical studies of ABO in blepharospasm and HFS.
Methods
The systematic literature review presented here is one part of a larger systematic review of all potential indications for ABO, the results of which will be presented separately per each relevant indication. The literature search strategy and methods for this systematic review were specified in advance and previously described in a protocol. 13 Components of the protocol include the literature search strategy, screening criteria, data extraction methods, and risk of bias appraisal used to assess studies selected for inclusion.
Screening criteria
Specific study characteristics of interest were defined in the protocol. They include study type-randomized controlled trials (RCTs) and other comparative clinical studies; patient population-adult patients with blepharospasm and HFS; treatment-ABO; and outcomesprimary and secondary efficacy, safety, and dosing.
Literature search strategy and data sources
The literature search strategy was developed using a combination of Medical Subject Heading (MeSH) terms and keywords. Keywords of relevance to the review of blepharospasm and HFS were abobotulinumtoxinA (alternative spellings included: abobotulinumtoxin A and abobotulinum Toxin A), Dysport, hemifacial spasm, blepharospasm, and clinical trial. Language (English only) and date limits (January 1991 to January 2013) were also applied. 13 Subsequently, the search was updated to include blepharospasm and HFS papers published between January 2013 and March 2015. Searches were performed in three foundational and comprehensive electronic medical literature databases (PubMed, Cochrane Library, EMBASE). Bibliographic reference lists of systematic reviews identified during screening were searched to identify any relevant studies that were not identified through the electronic database searches.
Study selection
At Level 1 screening, all publications reporting preclinical, Phase 1, prognostic/biomarker, genetic retrospective, registry, case report, and/or non-comparative studies were excluded, as were letters, consensus reports, editorials, and non-systematic reviews. Although, systematic reviews and meta-analyses were not included in their own right, they were used for identification of additional primary studies. At Level 2 screening, all publications that reported only biochemical or immunologic endpoints were excluded. Also at this stage, nonrandomized, controlled Phase 2 or 3 clinical trials, comparative longterm follow-up studies (e.g., open-label follow-up of randomized controlled clinical trials) and comparative prospective Phase 4 postmarketing trials were excluded, provided that adequate information from randomized Phase 2 and Phase 3 trials had been identified.
Data extraction
Study methodology, patient, and treatment-level data were extracted from the full text publications under predefined headings. Each included study underwent quality assessment for risk of bias based on Cochrane metrics. The quality assessment for RCTs systematically addresses six types of bias: selection, performance, detection, attrition, reporting, and other sources of bias not covered by other domains. If non-RCTs or other study types were deemed relevant for data extraction, quality assessment was performed using Transparent Reporting of Evaluations with Nonrandomized Designs (TREND) appraisal criteria for non-RCTs. 14 
Role of the funding source
The study was partially funded by Ipsen for data collection and editorial support. K.D. developed the protocol and data collection was coordinated by RTI Health Solutions and designates. Aside from procuring the data collection and editorial support, Ipsen did not contribute to the study conduct or reporting of results.
Results

Publications identified
We have previously reported the overall results of the larger systematic survey. 5 The current search identified five primary publications that evaluated ABO for the management of adult blepharospasm and HFS and met our search criteria. 
Efficacy in blepharospasm and HFS
All studies demonstrated the efficacy of ABO versus placebo in the management of blepharospasm and HFS; Table 1 provides an overview of efficacy and safety outcomes from each of the studies. The studies comparing the efficacy of ABO with other BoNT products generally showed equivalent efficacy, including latency and duration of action. 15, 16, 19 To evaluate the efficacy and safety of ABO in patients with blepharospasm, Truong and colleagues 17 16 performed a single-blind, randomized, parallel, comparative study to test the hypothesis that the optimal conversion factor for ABO to ONA is approximately 4:1 for adult patients with blepharospasm (n542) or HFS (n549). The primary outcome measures were the duration of effect, defined as the interval between the day of treatment and the date the patient reported a waning of effect, and the number of boosters needed. Secondary outcome measures were latency of effect, defined as the interval between the day of treatment and the start of symptomatic relief; clinical efficacy, measured as the relative percent improvement in the Blepharospasm Rating Scale, and frequency of adverse reactions. Eligible patients were randomized into two groups: one group received treatment with ABO using 10 U per point according to predefined schemes (blepharospasm: 5 points per eye giving a total dose of 100 U; HFS: 5 points around the affected eye and 2 points to the lower face giving a total dose of 70 U). The other group received ONA according to a similar injection pattern using 2.5 U per point. At this dose ratio, both ABO and ONA groups produced similar clinical efficacy and tolerability. For patients showing a positive response without the need of a booster, the duration of effect was 13.3¡5.9 weeks for the ABO group and 11.2¡5.8 weeks for the ONA group. The frequency of booster treatments was 23% in the ABO group and 12% in the ONA group (p50.26), with the booster dose always the same or similar to the one given in the first treatment. No statistically significant differences in all analyzed parameters between either patient groups or both drugs (P values NR) Secondary outcomes Treatment outcome between the third and last injection: stable in 91% of all patients 
Safety
The most common adverse effects (AEs) reported were ptosis for patients with blepharospasm and facial paresis for HFS patients. [15] [16] [17] [18] [19] Other AEs included blurred vision, lagophthalmos, diplopia, foreign body sensation, increased lacrimation, and aggravated dry eyes. 
Dosing
Dose ranges by individual study are given in Table 2 . The main muscle injected was the orbicularis oculi, although patients in the HFS study reported by Kongsengdao and Kritalukkul 19 also received injections into the orbicularis oris and patients in the study reported by Sampaio et al. 16 also received injections into the lower face (injection point not specified). Patients in the Kollewe et al. 18 study could also receive into the zygomaticus major, buccinator, corrugator, or frontalis muscles if there were residual contractions after the orbicularis oculi injections. Investigators in this study avoided making injections into the orbicularis oris muscle in order to prevent paralysis of the mouth. 
Discussion
The main aim of this systematic review is to summarize the relevant data on efficacy and safety profile of ABO in blepharospasm and HFS. Other reviews are available regarding assessment of BoNT for treatment of blepharospasm and HFS with no emphasis on the practical dosing of ABO. 6, 8 This is essential information as dosing units of one BoNT-A product are not interchangeable. In this review, all studies showed the efficacy of ABO in managing both blepharospasm and HFS. The studies generally showed that clinical improvements were seen within a week of injection and that the therapeutic effect lasted at least 3 months. Three of the five studies attempted to compare ABO with another BoNT-A product using a "dose ratio." Such ratios are notoriously hard to estimate, 20 efficacy and duration of effect might be observed as equivalent in studies of specific fixed dose relationships, but the same is not true for rates of AEs. 22 A key reason for this is that there is little to no increased therapeutic effect above an optimally effective dose, but the presence of excess toxin is associated with an increased risk of AEs, including unwanted spread of the toxin to other facial regions. The studies presented in this review provide the available evidence for the safetly profile of ABO for both blepharospasm and HFS. In the Nüssgens and Roggenkä mper study, the higher incidence of ptosis in the ABO vs. ONA groups may well represent overdosing due to use of both a higher starting ONA dose and the high conversion ratio (as discussed above). 15 The review provides the dose ranges of ABO that have been safely used in the various trials. In this respect it should be noted that the dosing table provided here is based on the published studies, and does not mean that other doses should not be applied; physicians should always use clinical judgment on dosing schedules dependent on the severity of impairment. This systematic literature review is part of a larger review where the use of ABO in other indications has also been evaluated. 13 When comparing the present results with the strength of the literature for blepharospasm and HFS, it is apparent that more high quality studies with ABO are required to inform practice. Based on our strict inclusion criteria a number of uncontrolled, exploratory studies were excluded and affected our sample size. While this obviously eliminated some clinically relevant information, this established methodology is considered necessary to avoid bias by using explicit, systematic methods. In summary, this systematic review provides the current evidence regarding safety and efficacy of ABO injection for blepharospasm and HFS. However, the review also revealed the lack of large trials of ABO to manage these two separate conditions.
